Biomarkers in psychiatry: drawbacks and potential for misuse
- PMID: 20150988
- PMCID: PMC2820448
- DOI: 10.1186/1755-7682-3-1
Biomarkers in psychiatry: drawbacks and potential for misuse
Abstract
For more than 20 years, researchers have attempted to identify diagnostic and prognostic biomarkers for psychiatric disorders including schizophrenia, major (unipolar) depression, and bipolar disorder. Advocates of this research contend that identifying such biomarkers will aid in the diagnosis of these disorders, as well as the possible development of effective psychiatric medications to treat them. Currently, there are no diagnostic tests available. This is largely due to the multi-factorial nature of psychiatric disorders. Biomarker testing of individuals is also prohibitively expensive because significant expertise is required to conduct tests and follow-up counseling for the patient is often necessary. It is cautioned that widespread biomarker testing could lead to negative consequences such as discrimination in health insurance and employment, as well as selective abortion.
References
-
- APA. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4. Washington, DC: American Psychiatric Association; 2000.
-
- WHO. International Statistical Classification of Diseases and Related Health Problems. 10 2007.
-
- Le-Niculescu HMJM, Mamidipalli S, Ogden CA, Kuczenski R, Kurian SM, Salomon DR, Tsuang MT, Nurnberger JI Jr, Niculescu AB. Convergent Functional Genomics of bipolar disorder: From animal model pharmacogenomics to human genetics and biomarkers. Neuroscience & Biobehavioral Reviews. 2007;31:897–903. - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources